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author and source are credited.The antigenic evolution of influenza:
drift or thrift?
Paul S. Wikramaratna, Michi Sandeman, Mario Recker and Sunetra Gupta
Department of Zoology, University of Oxford, Oxford OX1 3PS, UK
It is commonly assumed that antibody responses against the influenza virus
are polarized in the following manner: strong antibody responses are
directed at highly variable antigenic epitopes, which consequently undergo
‘antigenic drift’, while weak antibody responses develop against conserved
epitopes. As the highly variable epitopes are in a constant state of flux, cur-
rent antibody-based vaccine strategies are focused on the conserved epitopes
in the expectation that they will provide some level of clinical protection
after appropriate boosting. Here, we use a theoretical model to suggest the
existence of epitopes of low variability, which elicit a high degree of both
clinical and transmission-blocking immunity. We show that several epide-
miological features of influenza and its serological and molecular profiles
are consistent with this model of ‘antigenic thrift’, and that identifying the
protective epitopes of low variability predicted by this model could offer a
more viable alternative to regularly update the influenza vaccine than
exploiting responses to weakly immunogenic conserved regions.
1. Introduction
Influenza A viruses are responsible for between three and five million cases of
severe disease annually, and up to half a million deaths worldwide. These viruses
are classified into subtypes on the basis of variation in their envelope glyco-
proteins, haemagglutinin (HA) and neuraminidase (NA), and the event of their
replacement on a global scale is commonly referred to as an antigenic shift in
the virus population. In the last 100 years, we have experienced three such
shifts: in 1957, theH1N1 subtype that had been circulating since 1918was replaced
by H2N2; in 1968, H2N2 was replaced by H3N2; H1N1 was reintroduced in 1977
and has been cocirculating sincewithH3N2, although, in 2009, the current lineage
was replaced by one derived from pre-existing swine, avian and human viruses.
Each subtype, while in circulation, also undergoes a form of antigenic change cul-
minating in the sequential dominance of antigenically distinguishable strainswith
very limited cross-sectional genetic diversity. The underlying process is generally
visualized as a continuous and incremental transformation principally of the HA
glycoprotein, and goes by the name of antigenic drift.
While it has considerable appeal as a verbal explanation for the epidemic
behaviour of influenza, a formal link between the process of antigenic drift
and patterns of influenza strain replacement is very difficult to make. This is
because random mutation is much more likely to lead to a diffuse cloud of anti-
genic types on a variety of genetic backgrounds than the sequential emergence
of discrete strains. A simple, but biologically unsatisfactory solution is to restrict
the mode of mutation such that the virus population effectively travels in a pre-
ordained straight line or circle [1,2]. The alternative explanation is that most
mutants do not succeed, either because they are diffusing through genotypic
space along phenotypically neutral networks [3] or because they are out-
competed by strains that have achieved greater antigenic distance from the
preceding epidemic strains [4] or as a consequence of short-term strain-
transcending immunological interference [5]. These additional assumptions
can allow the virus population to progress in a linear manner through its avail-
able ‘antigenic space’ by counteracting the diffusive tendencies of antigenic
drift. A common assumption here is that the potential for variation of the HA
specific 
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Figure 1. The antigenic thrift model is based on a multi-locus representation
of the virus with each locus corresponding to an epitope region. This figure
shows how these may locate to the known antigenic sites on a monomer of
haemagglutinin (adapted from [71] & [72] with permission from OUP and
NEJM, respectively).
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Figure 2. The structure of the antigenic thrift model is shown here with
reference to a two locus and two allele system. A system of overlapping
compartments can be used to indicate the proportions immune to each strain
(z) and the proportion immune to antigenically related variants (w), from
which the proportion infectious with this strain ( y) can be deduced. In the
diagram, zax and wax are indicated by purple and red shading, respectively.
The notation ij  ax indicates all strains sharing alleles with ax. The
parameters b and 1/s, respectively, define the transmission coefficient and
infectious period of the virus, 1/m corresponds to the life expectancy of the
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to HA are strain-specific, such that immunity to one antigenic
type has no effect on any forms other than those that have
very recently diverged from it. We have challenged this
notion [6] by showing that epidemic behaviour of influenza
can be readily explained by assuming that each strain elicits
long-term partially cross-protective immune responses in
addition to strain-specific immunity. This model—which we
will henceforward refer to as the ‘antigenic thrift’ model
(as suggested byEddieHolmes)—departs from the convention-
al ‘antigenic drift’ hypothesis in a number of important ways:
(i) there are a restricted number of unique but inter-connected
antigenic states, (ii) the virus population has continuous
access to these states, but (iii) most of these are unsuccessful
owing to pre-existing partially cross-reactive immune
responses in the host population.
We have no shortage of sequence data on influenza, but
limited means as yet to use it to discriminate between com-
peting hypotheses concerning the antigenic evolution of the
virus population. Phylogenetic trees of influenza A exhibit
a spindly structure that has commonly been misinterpreted
as evidence of antigenic drift, but, in fact, simply indica-
tes that the populations repeatedly pass through tight
bottlenecks either as a result of selection or—as has recently
been shown—as a straight-forward consequence of sampling
sequences serially through time under neutral evolution [7].
It is clear that several of the models based on a process of
antigenic drift [3–5] are capable of generating the observed
trees; indeed, a principal focus of these efforts was to repro-
duce the ladder-like phylogeny of influenza A. It is as yet
unknown, however, whether the antigenic thrift model is
consistent with the phylogenetics of influenza. The antigenic
relationships between different strains of influenza can also
be determined using serological methods. An important
focus of this paper is how the antigenic thrift model stands
up to the scrutiny of sero-epidemiological analyses of the
antigenic evolution of influenza.
We first provide a review of the antigenic thrift model; we
then show how discriminating between epitopes of high and
low variability provides a novel means of reconciling the
dynamics of this model with empirical data on the antigenic
evolution of influenza. Finally, we discuss how we may use
improved serological techniques in conjunction with molecu-
lar methods to identify protective epitopes of low variability
that may enable us to address the problem of influenza
vaccination in a novel and practicable manner.host population and g measures the cross-immunity of a host gains from
having seen a related but not identical variant.2. The antigenic thrift model
Figure 1 provides a caricature of the fundamental assump-
tions of the antigenic thrift model in terms of how the
various epitopes might map onto the structure of an HA
monomer. In essence, the model combines highly variable,
strain-specific epitopes (here visualized as surrounding the
binding pocket) as well as epitopes of low to intermediate
variability that are shared between strains. The model
argues that immune responses against the latter are critical
determinants of the protection against disease and onward
transmission and drive the population dynamics of influenza
in concert with antibodies directed at the uniquely strain-
specific epitopes. Those individuals who have been exposed
to a particular strain—as defined by a combination of theseepitopes—have lifelong immunity to that same strain, but
also have partial immunity (also lifelong) to strains related
to it by virtue of possessing common epitopes. This network
of cross-protection acts to limit the emergence of new anti-
genic types and can thus reconcile the high mutation rates
of influenza with the dominance of a single antigenic type
in each season.
Figure 2 summarizes the model structure using a simple
schematic based on a system with only two relevant loci
and alleles a and b at the first locus and x and y at the
second. It is assumed that individuals who have been
exposed to a particular strain (say ax, as shown in the dia-
gram) are immune to further infection by the same strain,
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Figure 3. Strain dynamics within a f2,3,5g antigenic structure with
(a) g ¼ 0.95 and (b) g ¼ 0.8 (b ¼ 292; s ¼ 73; m ¼ 0.02).
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alleles with it (in this example, ay and bx) have a reduced
probability (12 g) of transmitting the strain when infec-
ted; the parameter g reflects the strength of allele-specific
responses in preventing transmission. This structure can be
easily generalized to multiple loci or epitopes with different
levels of variability (i.e. number of possible alleles); we will
henceforward use the notation f2,3,25g, for example, to
indicate that there are three loci with 2, 3 and 25 alleles,
respectively, and [i,j,k] to designate a particular strain or
combination of alleles.
Mutation is not explicitly considered in thismodel. Instead,
and since the model is deterministic, each possible antigenic
variant is continuously present within the viral population.
It is difficult to ascertain how this translates into an explicit
mutation rate, but it does mean that at the precise moment a
gap emerges in the network of host immunity, this gap can
be exploited by any and all appropriate antigenic variants.
Thus, it is this network of host immune responses, and not
the mutational capability of the virus, that constrains observed
antigenic diversity within the premise of antigenic thrift.
Multi-locus systems are capable of exhibiting two kinds of
structuring, as shown in figure 3. At high levels of immune
selection and provided that there is an equal number of poss-
ible alleles at each locus, discrete strain structure emerges
with the stable maintenance of a set of strains that do not
share alleles [8,9]. This discrete antigenic structure tends to
break down in deterministic multi-locus models, when
unequal numbers of allelic variants are instead possible at
each locus but are recovered by the inclusion of stochastic
processes [9]. At intermediate levels of immune selection,
cyclical or chaotic strain dynamics (CSS) occurs [10]. We
posit that the epidemic behaviour of influenza maps onto
an area of CSS that exhibits high single strain dominance
[6]. Figure 3b provides an example of this kind of dynamicfor a f2,3,5g system; figure 4 traces a section of the antigenic
trajectory of the virus population within a three-dimensional
space that can be used to represent the relationships between
all possible strains.
Single strain dominance can be quantified by the mea-
sure of 1 by comparing the relative prevalence of the two
most common antigenic variants within single epidemics
(figure 3), and then averaging across extended periods of
time [6]. More formally, averaging across each of P epidemics:
1 ¼ 1
P
XP
i¼1
yimaxyisub
yimax
:
High 1, therefore, indicates strong single strain domi-
nance as apparent for the antigenic evolution of influenza.
Single strain dominance peaks at certain intermediate levels
of g [6], but also shows a dependence on epitope architecture.
Figure 5a shows how different multi-locus systems, all with
32 total variants, differ in the region of g where they exhibit
strong single strain dominance. Interestingly, the combi-
nation that most favours strong single strain dominance
here is f8,2,2g, while those that do least well are f16,2g and
f2,2,2,2,2g, which respectively minimize and maximize con-
nectivity. The complexity of the relationship between high 1
and antigenic architecture is further demonstrated in figure
5b by comparing structures with 400 variants each. It is
clear, nonetheless, that structures with high variability (HV)
at every locus rarely tend to exhibit 1. 0.5 (even though
they are in CSS) and a single-locus system with 400 alleles
will not exhibit any oscillations whatsoever. Those combi-
nations that perform well on this measure tend to contain
some epitopes of low variability, but can also contain at
least one highly variable locus.3. Serological signatures of antigenic evolution
A common method for recording antibody levels in sera
of either naturally or experimentally infected animals is the
haemagglutination inhibition (HI) assay. HI assays exploit
the ability of the influenza virus to bind to sialic acid recep-
tors, and thus agglutinate avian and mammalian red blood
cells [11]; the level of dilution at which a serum sample
stops being able to prevent agglutination determines its HI
titre. Published HI tables of human influenza A based on
antisera raised in ferrets tend to show very high titres to
the homologous isolate, but highly variable titres to tem-
porally close isolates and, usually, a complete loss of
reactivity against strains isolated more than a few years dis-
tant from the considered strain. This has commonly been
interpreted as evidence of gradual antigenic drift, with each
dilution step corresponding to an increase in antigenic dis-
tance. We have previously shown that such empirical data
are consistent with the antigenic thrift model under the
sampling scheme and multivariate analysis commonly used
in their representation in two-dimensional antigenic space
[6]. Indeed, the zig-zagging movement through antigenic
space revealed by sophisticated cartographic methods
applied to the evolution of H3N2 since 1968 [12] may be
better explained by the antigenic thrift model. We have
suggested that the apparent continuous increase in antigenic
distance may be due to the censoring of entries between non-
adjacent time-points, and that this signature of drift would
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Figure 4. The f2,3,5g antigenic structure can be visualized in three-dimensional space with each axis representing a set of alleles at a particular locus, such
that each point corresponds to a different antigenic variant. (a) Cross-reactivity against variant [2,2,5] extends within this space along the shaded green planes.
(b) An example trajectory of the virus population through this space.
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of the elements of the HI data matrix. This may be under-
stood with reference to figure 4b: erasing the links between
non-consecutive strains would have the effect of stretching
out the trajectory, but nonetheless preserve some of the
inherent transverse movement.
There are at least two alternative interpretations that
reconcile the absence of reactivity by HI between non-adjacent
time-points with the antigenic thrift model. The first is that HI
assays selectively provide information on the unique strain-
specific epitopes rather than the shared epitopes of limited
diversity: in other words that the antibodies that prevent
haemagglutination are directed only at the highly variable
epitopes putatively clustering around the receptor-binding
pocket as shown in figure 1. Figure 6a shows the antigenic
relationships between strains within a f2,3,25g system as
revealed by an assay that focuses solely on the third, highly
variable, epitope region. A strong diagonal signature is
observed, offering the impression of linear movement through
antigenic space when in fact the population is actually zig-
zagging within it in a manner analogous to that shown in
figure 4b. Assuming instead that the magnitude of the HI
titre depends on the precise number of shared epitopes
(figure 6b), we can again find a strong diagonal signature,
but with more evidence of clustering of similar antigenic var-
iants in time, as seen in human HI data and by genetic
analysis of influenza virus sequence evolution [13]. This
emerges as a natural property of this model, owing to the
time-scales at which epitope-specific immunity declines. In
effect, as older hosts die, population-level immunity against
the strains that they have specifically experienced wanes,
thus creating gaps in the network of herd immunity that
may be occupied by similar strains. This can lead to a
sequence of antigenically related epidemics, until eventually
a completely discordant allele combination is favoured anda cluster jump occurs. This is evident even in systems of
low dimensionality such as the f2,3,5g example in figure 3b:
the sequence [2,1,1]! [2,1,3]! [1,3,5]! [1,3,3] can be
interpreted as a cluster transition between [2,1,*]! [1,3,*].
Another consideration in the interpretation of HI is
that the laboratory animals used in generating the data may
produce a response that is more focused towards the varia-
ble regions of HA than humans upon natural infection.
HI assays are typically performed on post-infection antisera
raised in ferrets and there is evidence suggesting that the
cross-reactivities can be different to that of sera to the same
isolate raised in mice and rabbits [14,15]. To our knowledge,
no comparative study has been performed on post-infection
sera taken from ferrets and humans or ducks and chickens,
or indeed for many of the pairs of animals, where post-
infection sera from the former are used to infer antigenic
relationships in the latter.
Antigenic relationships between influenza strains can also
be interrogated using microneutralization (MN) assays, where
the virus is mixed with varying dilutions of serum and then
inoculated into culture, and the presence of virus-specific anti-
bodies in the serum is indicated by impaired or absent viral
replication. HI titres correlate well with the results of MN
assays [16], suggesting that both are detecting antibodies
against highly variable epitopes putatively clustering around
the receptor-binding pocket. However, discrepancies between
the two assays—such as antisera with high neutralization titre
but low or even absent HI titre or vice versa—have been
reported for avian [17,18] and swine [19] influenza, and
there are monoclonal antibodies that neutralize but do not
inhibit haemagglutination and vice versa [20,21], suggesting
that they do have different (although possibly overlapping)
specificities. In theory, MN assays and other sophisticated
serological techniques currently are in development [22],
should be able to detect additional antibody responses against
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performed on the appropriate sera.
There is also growing evidence that antibodies targeting
the stem region of HA (HA2) are capable of mediating protec-
tion from influenza infection. Such antibodies appear capable
of recognizing a variety of different subtypes and strains,
resulting also in protection of mice from lethal infection
upon challenge (as reviewed by Yewdell [23]). In particular,
monoclonal antibodies against HA2 have been shown
capable of neutralizing drift variants of H3N2, and also pro-
tecting mice from challenge by the same variants [24]. Such
responses do not appear to block viral attachment, and there-
fore do not exhibit cross-reactivity in the HI test, but may
instead inhibit viral fusion [24,25]. The epitopes targeted by
this class of antibody, may correspond to those of LV posited
by the model of antigenic thrift, perhaps not least because
escape from them can be precipitated by single point
mutations in HA2 [26].Epitopes of LV may also be located on NA; antibodies
against these would act to prevent release of virus from the
infected cell. The recent application of antigenic cartography
methods toNAinhibitiondata reveals ahighdegreeof asymme-
try that is consistent with the antigenic thrift model. Sandbulte
et al. [27] further suggest that antigenic evolution of NA may
account for unexpected vaccine failures, where there is a good
match based on HI data, highlighting the potential importance
of more than just HI data in understanding the ways in which
the virus can change to evade immune recognition.4. Re-emergence of antigenic types
Perhaps, the most compelling evidence in support of the
antigenic thrift hypothesis comes from the antigenic analysis
performed in the wake of the 2009 H1N1 pandemic. Multiple
serological studies have found evidence in the elderly of
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Figure 6. Pseudo HI tables constructed from the strength of cross-reactivity between the dominant variants of the ith and jth epidemics within a f2,3,25g
antigenic space under different assumptions about the HI test: (a) HI only picks up the most variable epitope and strains only cross-react in the test (shown in black)
if they are identical at this epitope and (b) HI titre depends on the number of shared epitopes with black/dark grey/light grey/white indicating epidemic strains that
share 3/2/1/0 alleles, respectively. Epidemics were defined as local maxima in total prevalence more than 1.645 standard deviations from the mean, in line with
[73]. (g ¼ 0.8, b ¼ 292, s ¼ 73, m ¼ 0.02).
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strain [28–35], and this appears to explain the low rates of
disease in this age group during the pandemic [30,35–37].
Infection of both ferrets and mice with A/New Jersey/76
has been shown to confer strong cross-protection against
challenge with 2009 pandemic H1N1, together with high
cross-reactivity in the HI test [38–41]. In humans, receipt of
the A/New Jersey/76 vaccine has been implicated in
superior antibody responses against the 2009 strain [42].
H1N1 isolated prior to 1950 has also been shown to elicit
significant, though less complete, protection upon challenge
by pandemic H1N1 in both animal models, despite only
weak cross-reactivity within HI and MN tests [38–41,43].
An inability of later seasonal isolates to protect against pan-
demic H1N1 challenge has been linked to glycosylation
patterns on the globular head of HA, which may also explain
why not all pre-1950 isolates appear to protect equallywell [41].
Similar serological and clinical observations of cross-
reactivity and clinical protection in the elderly have also
been made in each of the previous three pandemics [44].
This could be explained by original antigenic sin (a phenom-
enon by which individuals continue to produce antibodies
against the strain they were first infected with, even when
challenged by a different strain/subtype), but this would
still require a high degree of similarity between the returning
strain and those to which they had been previously exposed.
There are hints of re-emergence of certain epitopes in anti-
genic analyses performed on H2N2 influenza, with a number
of monoclonal antibodies raised against a 1957 strain cross-
reacting strongly with a strain isolated in 1964, but not with
a 1963 strain [45]. Antigenic analyses of influenza in pigs
and birds are also suggestive of the re-emergence of antigenic
types. Contractions in antigenic distance can be observed
among populations of swine H1 viruses in the USA [46],
and HI tables of H5N1 isolates from a variety of avian species
demonstrate discordances in cross-reactivity [47] that aremore
easily explained by recycling of variants than incremental
accrual of antigenic distance.5. Discussion
Many features of the epidemiology of influenza can be
explained by assuming that neutralizing antibodies act
upon shared epitopes of LV as well as upon epitopes of HV
that may be unique to a particular epidemic strain. We
argue here that the use of HI assays has focused our attention
on HV epitopes, but immune responses against these alone
cannot produce a sequential emergence of antigenic types.
We propose that the structuring of the virus population is
achieved principally through immune responses against the
LV epitopes which are not adequately represented in HI
tables as they have a limited role in the binding of the virus
to RBC. The existence of these additional LV epitopes is consist-
ent with the observation that clinical protection andHI titre are
logarithmically related, with limited improvement in protec-
tion beyond a certain (fairly low) titre [48], and also explains
why high vaccine efficacy is sometimes observed even when
HI data indicate that the incoming influenza strain has changed
[49]. The results of early studies showing induction of superior
HI titres with inactivated vaccines, but inferior protection from
disease and shedding when compared with live vaccines [50]
can be justified within this framework, if the latter induce a
broader response that includes the LVepitopes. It is also tempt-
ing to speculate that some of the effects of original antigenic sin
may be attributed to the skewing of antibody responses
towards LV epitopes in later infections. In other words, a
naive individual would produce antibodies to both HV and
LV epitopes, but selectively towards LV epitopes in subsequent
infections since they are shared between strains. They would
thus maintain a strong HI response to the original strain, but
may not show high HI titres to more recent infections. A
recent Japanese study [51] showing that sera from young chil-
dren were prone to recognize only the antigenic site B1 of the
HA1 region of H3, in contrast to older individuals who had
broad recognition, supports this idea.
Our model is not unique in invoking multiple com-
ponents of immunity, but differs critically from other
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HV and LV epitopes, which both elicit strong specific life-
long immunity and do not include epitopes that induce
short-term non-specific immunity (as in [5]). The validity of
the antigenic thrift model rests on the existence of LV epi-
topes: identifying these would thus allow us to discriminate
between competing hypotheses concerning the antigenic
evolution of influenza (although they are by no means
mutually exclusive), but, more importantly, could form the
basis of a new vaccine that would release us from our depen-
dence on monitoring change in the HV epitopes, and could
complement the use of both antibody and T-cell-based vac-
cines towards fully conserved but weakly immunogenic
epitopes that are currently under development [52].
How do we go about looking for LV epitopes, if they
are not visible by HI? We anticipate that the dissection of
antibody responses in human sera using MN assays, in con-
junction with other more advanced techniques in the pipeline
[22], will assist in identification, but we can also use molecu-
lar sequencing methods? It has long been recognized that the
virus possesses a number of discrete antigenic sites [53], and
several studies indicate that the number of amino acid differ-
ences in these sites is a better predictor of vaccine efficacy
than HI data from ferrets [54,55]. We have previously high-
lighted that there is LV at 18 amino acid positions that have
been identified by Bush et al. [56] as being under positive
selection in H3N2; several of these are represented among
the key immunodominant positions identified by pairwise
comparison of consecutive epidemic strains [12,57] and by
analysis of change in net charge [58]. Amino acid changes
in the HA epitopes of H2N2 [45], H1N1 [59] and highly
pathogenic H5N1 [60] also seem to be subject to strong
restrictions. Epistatic interactions between sites, as documen-
ted by Kryazhimskiy et al. [61], may act to further reduce the
potential nodes within antigenic space that may be occupied
by the virus or favour a particular combination even under a
very slight increase in transmissibility [62]. Sequence simi-
larities between epitopes of 1918 H1N1 influenza and the
2009 pandemic strain have been used to justify pre-existing
immunity to the latter [63,64]; similar arguments have also
been made for the presence of neutralizing antibodiesamong individuals born before 1957 by comparing the HA
sequences of 1957 and 2009 H1N1 strains [65]. Many of
these studies rely on HI assays to discriminate between
strains: the antigenic thrift model would predict that this
method would selectively emphasize the role of mutations
near the receptor-binding sites and, indeed, this seems to be
the case in a recent study [63]. Rudneva et al. [63] also recorded
some discordance between HI and ELISA studies, suggesting
that the use of HI may not be sufficient to pick-up the
LV epitopes. Newer methods such as panning of whole-
genome-fragment phage display libraries (GFPDL) with
convalescent human sera [66], tend by contrast to direct our
attention towards weakly immunogenic conserved epitopes,
but may be deployed to pick out LV epitopes with finer resol-
ution of HA and NA gene fragments. It is also important that
these analyses include considerations of effects of glyco-
sylation, alteration of biophysical properties [67], complex
interactions between residues at antigenic sites both within
and between HA and NA [61,68,69] and potential effects of
antibody interference [70]. Combining these techniques to
elucidate the functional repertoire of human antibodies to
influenzawill be invaluable in resolving towhat extent its epi-
demiology is determined by epitopes of LV, andwhether these
may be used to confer broader protection.Note added in proof
Zinder et al. [74] have recently shown that the phylodynamics
of influenza can be readily generated within a similar frame-
work with a number of epitope regions of limited diversity,
under a somewhat different cross-immunity structure, pro-
vided it is also mutation-limited. This suggests that it will
be difficult to discriminate between competing hypotheses
of antigenic evolution on the basis of their ability to generate
realistic phylodynamic patterns.
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